TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00544570
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02928965
Drug: Minocycline
Normalized name: Minocycline
DrugBank: Minocycline (DB01017)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Capsules containing 100mg minocycline (modified release), administered orally by the patient, two per day for the first two weeks and then three per day for the reminder of the 12 month treatment period in addition to standard therapy.
Study: NCT02928965
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo with appearance of over - encapsulated minocycline
Study: NCT00544778
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01834989
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01939613
Drug: colloids
Normalized name: Technetium (99mTc), particles and colloids
Approvals — FDA: no, EMA: no, PMDA: no
Description: TMMU group allows for administration of colloids early,while Parkland group infuse colloids 24 h after burn injury.
Study: NCT00832299
Drug: FOLFOX
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 cycles of neo-adjuvant mFOLFOX6
Study: NCT04456673
Drug: Inhaled Corticosteroid
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: Inhaled Powder~Route of administration: Oral inhalation
Study: NCT04456673
Drug: Inhaled Long-Acting Beta Agonist
Normalized name: Sinex Long-Acting Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: Inhaled Powder~Route of administration: Oral inhalation
Study: NCT04456673
Drug: Inhaled Long-Acting Muscarinic Antagonist
Normalized name: Sinex Long-Acting Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: Inhaled Powder~Route of administration: Oral inhalation
Study: NCT04456673
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: Solution for injection~Route of administration: Subcutaneous
Study: NCT02741739
Drug: REGN1033
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04382040
Drug: ArtemiC
Normalized name: ARTEMISININ 0.6 g in 100 g / CURCUMIN 2 g in 100 g / ASCORBIC ACID 6 g in 100 g / BOSWELLIA SACRA BARK 1.5 g in 100 g ORAL SPRAY, SUSPENSION [ArtemiC Rescue]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment will be sprayed orally twice a day for the first 2 days in the treatment period
Study: NCT04382040
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment will be sprayed orally twice a day for the first 2 days in the treatment period
Study: NCT03739268
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo powder dissolved in water 1,600 mg three times a day for 17 days
Study: NCT01096875
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1tb/day once daily for two weeks prior to surgery
Study: NCT00401310
Drug: Comparator: Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo IV infusions 1hr/daily over 7 days.
Study: NCT00822185
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose is injected i.v. over 2 minutes to 2 subjects per dose level: 5 mcg/kg
Study: NCT00822185
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose is injected i.v. over 2 minutes to 2 subjects per dose level: 30 mcg/kg
Study: NCT01916954
Drug: 3-day artemether-lumefantrine
Normalized name: Artemether/lumefantrine
DrugBank: Lumefantrine co-artemether (DB13085)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01916954
Drug: 5-day artemether-lumefantrine
Normalized name: Artemether/lumefantrine
DrugBank: Lumefantrine co-artemether (DB13085)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02007798
Drug: normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 ml per bag
Study: NCT04647773
Drug: HSK16149 20mg BID
Approvals — FDA: no, EMA: no, PMDA: no
Description: HSK16149 20mg, orally twice a day, treatment period; 13-weeks fixed dose.
Study: NCT02382432
Drug: Pethidine 0.4mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2ml intravenous bolus slowly injected in 2minutes.
Study: NCT04647773
Drug: HSK16149 40mg BID
Approvals — FDA: no, EMA: no, PMDA: no
Description: HSK16149 40mg, orally twice a day, treatment period; 13-weeks fixed dose.
Study: NCT04647773
Drug: HSK16149 80mg BID
Approvals — FDA: no, EMA: no, PMDA: no
Description: HSK16149 80mg, orally twice a day, treatment period; 1-week titration and 12-weeks fixed dose.
Study: NCT04647773
Drug: Placebo BID
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, orally twice a day, treatment period; 13-weeks fixed dose.
Study: NCT00942604
Drug: Vehicle gel
Normalized name: vehicle gel base no.61
Approvals — FDA: no, EMA: no, PMDA: no
Description: two day treatment
Study: NCT00553891
Drug: placebo nasal spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: One spray in each nostril once daily for 3 months.
Study: NCT01143246
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 11 mg mannitol reconstituted with 5 ml of sterile 0.9% sodium chloride solution.
Study: NCT00161148
Drug: Probiotics
Normalized name: probiotics
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01077908
Drug: Best available antiviral drug therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1. Intravenous ganciclovir 5mg/kg twice daily~2. Oral valganciclovir 900mg twice daily~3. Intravenous foscarnet 90 mg/kg twice daily
Study: NCT04163419
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 10 mg SC
Study: NCT02129439
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention of placebo-treated subjects does not vary to SB012-treated subjects.~The treatment phase lasts 28 consecutive days. Placebo will be administered for the first time at the study site in the morning on Day 1 (Administration training by study site staff). The final administration will be performed at the study site in the morning of Day 28. On all other treatment days (Day 2 to Day 27), the IMP/Placebo will be self-administered by the subject at home. Placebo will be administered with a volume of 30ml.~The IMP/Placebo is formulated as an enema (plastic rectal tube) and will be administered in this clinical trial by the rectal route. The enema is a ready-for-use preparation. No further preparation steps are required.
Study: NCT02992743
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide will be used as a lymphodepleting chemotherapy.
Study: NCT00017108
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03636503
Drug: PF04518600
Approvals — FDA: no, EMA: no, PMDA: no
Description: In the presence of tumor-associated antigens (TAAs), this may promote a T-cell-mediated immune response against TAA-expressing tumor cells. OX40
Study: NCT00381680
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT00381680
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IT or IV
Study: NCT00381680
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00381680
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV or PO
Study: NCT02222623
Drug: NPH
Normalized name: ZENPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: NPH 2/3 of the total daily dose given with breakfast, 1/3 of the total daily dose given at bedtime. The initial dose is calculated using the patient's weight or using the basal insulin dose prior to hospitalization.
Study: NCT00381680
Drug: mercaptopurine
Normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT01884467
Drug: Gentamicin
Normalized name: Gentamicin
DrugBank: Gentamicin (DB00798)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Comparison of Gentamicin versus placebo
Study: NCT01884467
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01934101
Drug: CHR-5154
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHR-5154
Study: NCT01934101
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01012765
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to indacaterol o.d. delivered via SDDPI
Study: NCT02852876
Drug: ASP2151
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral
Study: NCT02852876
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral
Study: NCT01651156
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02071823
Drug: BIA 9-1067
Normalized name: Oatmeal 10 mg in 1 mL TOPICAL CREAM [BIA Eczema Relief]
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single oral dose of 50 mg (2 x 25 mg capsules) was administered in the morning of each study period under fasting or fed conditions. The two single dose administrations were separated by a wash-out of 7 days.
Study: NCT01143129
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo solution in a comparable amount to the experimental drug (0.05 mL/kg)
Study: NCT00145795
Drug: Current Regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00570492
Drug: Placebo nasal spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo nasal spray
Study: NCT04202601
Drug: IBI310
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arms 1: Neoadjuvant therapy group, 20 patients Drug: IBI310 1 mg/kg Q6W on Day 1 by IV infusion. Intervention：Perioperative Sintilimab+ IBI310 are administered for 1-3 (6-18 weeks) cycles followed by 4 postoperative cycles (12 weeks) with Sintilimab monotherapy .~Arms 2: first-line therapy group, 30 patients Drug: IBI310 1 mg/kg Q6W on Day 1 by IV infusion. Intervention：Sintilimab + IBI310 are administered for 1-3 (6-18 weeks) cycles followed by Sintilimab monotherapy for up to 2 years.~Arms 3: ≥second-line therapy group, 30 patients Drug: IBI310 1 mg/kg Q6W on Day 1 by IV infusion. Intervention：Sintilimab + IBI310 are administered for 1-3 (6-18 weeks) cycles followed by Sintilimab monotherapy for up to 2 years.
Study: NCT00830726
Drug: Pharmacologic and mechanical heart failure treatment
Normalized name: porcine heart preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimised, standard, evidence based heart failure therapy including the use of biventricular pacing.
Study: NCT01099176
Drug: To compare monotherapies and combined therapy with each other
Normalized name: Other cardiac therapy combination products in ATC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each patient received two tablets per day. Time interval between pills - 12 hours.~In monotherapies patients received one active tablet and one placebo, in combined treatment both pills were active and in placebo group patients taken two placebo tablets
Study: NCT00003401
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00044616
Drug: Fluoxetine
Normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01695707
Drug: Placebo (for pioglitazone)
Approvals — FDA: no, EMA: no, PMDA: no
Description: see Arm Description
Study: NCT01437657
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching RO4917523 placebo orally daily, 6 weeks
Study: NCT01437657
Drug: RO4917523 0.5 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg orally daily, 6 weeks
Study: NCT01437657
Drug: RO4917523 1.5 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mg orally daily, 6 weeks
Study: NCT00059462
Drug: HAART
Normalized name: porcine heart preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: HAART alone
Study: NCT00434291
Drug: TG-873870(Nemonoxacin)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01094847
Drug: DWJ1252
Approvals — FDA: no, EMA: no, PMDA: no
Description: tablet(oral) administration following the schedule of each arm
Study: NCT02354898
Drug: BBI503
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03223961
Drug: EPREX
Normalized name: Eprex
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 000 U/week for at least 12 weeks
Study: NCT01804400
Drug: QAW039
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01804400
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01587716
Drug: GSK2339345 (Inhaled) Single Dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250, 1000 and 2000 microgram (proposed doses)
Study: NCT01955824
Drug: 1% lignocaine
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01955824
Drug: 2% lignocaine
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03332225
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment with Placebo
Study: NCT01093157
Drug: Adrenocorticotrophic hormone ACTH
Approvals — FDA: no, EMA: no, PMDA: no
Description: There will be two arms to the study: one arm receive 40 units and the second arm 80 units of the ACTH gel subcutaneously both given in a dose escalating frequency beginning at once every two weeks escalating to a maximum of twice per week over a total of three months exposed.An ammendment(approved by Health Canada and the UHN IRB allows an additional 1 month of the perscribed therapy of ACTH )if there is an improvement in proteinuria at the end of the 3 month exposure.
Study: NCT01626469
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT03644966
Drug: Antibiotics
Normalized name: Antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Per Infectious Disease Society guidelines for Antimicrobial treatment of uncomplicated cystitis and pyelonephritis in women
Study: NCT03549182
Drug: ATD treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral administration of ATD (100g)(Acute Tryptophan Depletion)
Study: NCT03549182
Drug: placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral administration of placebo (102.3g)
Study: NCT00100269
Drug: Menevit anti-oxidant
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02839200
Drug: Placebo 1
Normalized name: placebo 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules matching ACT-541468 capsules
Study: NCT02839200
Drug: Placebo 2
Normalized name: Ethinyl Estradiol/Norethindrone Acetate;Placebo 20 MCG-1 MG; NA Oral Tablet, Disintegrating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules matching over-encapsulated zolpidem
Study: NCT03666494
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: As part of the patient's anesthetic induction, they will receive fentanyl.
Study: NCT00986765
Drug: Lovenox® (enoxaparin)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injectable solution 4000 UI
Study: NCT00986765
Drug: Aspegic ® (Aspirin)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg/day
Study: NCT02077452
Drug: HMS5552
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02077452
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02874378
Drug: 0.9%NaCl solution
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02543918
Drug: Boostrix®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered by IM injection
Study: NCT00975000
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally following the same dosing regimen as the experimental arm.
Study: NCT01869959
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT00503763
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00110448
Drug: No aspirin
Normalized name: XS No Aspirin PR
Approvals — FDA: no, EMA: no, PMDA: no
Description: No aspirin use
Study: NCT00380783
Drug: AGN 203818
Normalized name: VITEX AGNUS-CASTUS WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03728101
Drug: Simvastatin, Dabigatran Etexilate
Approvals — FDA: no, EMA: no, PMDA: no
Description: The subjects receive dabigatran etexilate with and without simvastatin administration
Study: NCT01817764
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered via ACCUHALER/DISKUS or NDPI. Dry white powder administered as one inhalation each morning and evening via ACCUHALER/DISKUS (1 strip with 60 blisters containing placebo) OR once-daily in the morning via NDPI (2 strips with 30 blisters each, containing placebo)
Study: NCT00041561
Drug: inhaled nitric oxide
Normalized name: nitric oxide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: inhaled nitric oxide will be given at 5 ppm until day 28 or extubation
Study: NCT02926833
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered intravenously
Study: NCT03561480
Drug: 0.9% Normal Saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be in the form of normal saline administered over same time period as equivalent Ferinject® administration. IV drip infusion or undiluted bolus injection with a minimum administration time of 15 minutes (200mL as infusion or 20mL as bolus injection) for body weight ≥50 Kg or 6 minutes (100mL normal as infusion or 10mL as bolus injection) for body weight \<50 Kg.
Study: NCT00329433
Drug: Heparin
Normalized name: Heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The patients who are randomized to the Heparin (standard of care) group will receive subcutaneous injections of heparin three times a day (0900, 1300 and 2100).
Study: NCT01246193
Drug: CKD-828(FDC)
Normalized name: DYE FDC BLUE #1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: Telmisartan 80mg + S-Amlodipine 2.5mg(FDC) Tablet, Oral, Once Daily
Study: NCT02046551
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04085354
Drug: Dapoxetine and folic acid.
Approvals — FDA: no, EMA: no, PMDA: no
Description: The distribution of the patients among the four groups was based on randomized coded cards, so the patients were unaware of the type of the drugs used. Group 3 was given on-demand 30 mg dapoxetine 1-2 h before intercourse and daily oral supplementation of 0.5 mg folic acid.
Study: NCT00444028
Drug: inhaled Placebo (0 mg)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single placebo dose of inhaled loxapine
Study: NCT01578486
Drug: salsalate
Normalized name: Salsalate
DrugBank: Salsalate (DB01399)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: open-label trial of salsalate 3g/day for 12 weeks.
Study: NCT04292899
Drug: Standard of Care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of Care Treatment for COVID-19 Infection
Study: NCT00003576
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01714726
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 iv infusion on Week 0 and Week 4
Study: NCT01497223
Drug: MGCD290
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 Oral Dose Administration
Study: NCT01846442
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo vaginal suppository containing 0.0% (0 mg) DHEA; daily dosing with one suppository for 12 weeks.
Study: NCT03996694
Drug: Belbuca 300 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Belbuca 300 µg buccal film
Study: NCT03996694
Drug: Belbuca 600 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Belbuca 600 µg buccal film
Study: NCT03996694
Drug: Belbuca 900 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Belbuca 900 µg buccal film
Study: NCT03996694
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo buccal film and oral placebo
Study: NCT01171794
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3 x 200mg (600mg total) x tid and one dosing on the subsequent day ( 4 doses total)
Study: NCT01171794
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: identical number of visually identical tasteless pills as ibuprofen arm
Study: NCT02379091
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Namilumab placebo-matching subcutaneous injection
Study: NCT02379091
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate tablets
Study: NCT02379091
Drug: Folic/folinic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Folic/folinic acid tablets
Study: NCT00276341
Drug: EGb 761® (Tanakan®)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01511367
Drug: Flutiform
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50/5ug (fluticasone/formoterol) 2 puffs twice daily
Study: NCT01673542
Drug: DEXERYL
Normalized name: Dexeryl
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04120116
Drug: FX-322 (Two Doses)
Normalized name: Prevail-FX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive two doses of FX-322.
Study: NCT04120116
Drug: FX-322 (Four Doses)
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive four doses of FX-322.
Study: NCT04120116
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive Placebo.
Study: NCT01724099
Drug: Euiiyin-tang
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Korean medicinal herbal drug
Study: NCT01724099
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo drug, same odor and formula as Euiiyin-tang
Study: NCT01886053
Drug: Faropenem（low-dose group)
Approvals — FDA: no, EMA: no, PMDA: no
Description: dosage form: Injection dosage:2400 mg frequency: twice a day
Study: NCT03523988
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen gel capsule
Study: NCT03523988
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen gel capsule
Study: NCT00665366
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets, Oral, 0 mg, once daily, 12 weeks
Study: NCT00066157
Drug: Transdermal estradiol
Normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50 micrograms (low-dose) or 100 micrograms (high-dose) transdermal 17-ß-estradiol patch, changed every 3 days, for 12 months